Semaglutide vs Tirzepatide vs Retatrutide in Muscat, Oman
Compare semaglutide, tirzepatide, and retatrutide for weight loss in Muscat, Oman. Learn how they work, key differences, and what to know before treatment.
If you are researching weight loss injections in Muscat, Oman, three names come up again and again: semaglutide, tirzepatide, and retatrutide. Semaglutide is the active ingredient in Ozempic and Wegovy, tirzepatide is the active ingredient in Mounjaro and Zepbound, and retatrutide is a newer investigational medication still being studied in Phase 3 clinical trials.
Although these medications are often grouped together, they are not the same. They target different hormone pathways, deliver different average weight-loss results in clinical trials, and are not all equally available today.
How do these medications work?
These medications belong to a group often called incretin-based therapies. They help regulate appetite, food intake, blood sugar, and how the body handles energy.
Semaglutide works on the GLP-1 receptor.
Tirzepatide works on both GIP and GLP-1 receptors.
Retatrutide works on GIP, GLP-1, and glucagon receptors, which is why it is often described as a triple-agonist medication.
In simple terms, semaglutide helped start the modern weight-loss medication era, tirzepatide built on that by targeting two pathways instead of one, and retatrutide is being developed as the next step beyond both.
Semaglutide: the established GLP-1 option
Semaglutide is the active ingredient in Ozempic and Wegovy. For accuracy, it is important to separate the brand names: Wegovy is FDA-approved for chronic weight management, while Ozempic is not FDA-approved for weight loss and is approved for type 2 diabetes.
Semaglutide became widely known because it showed strong and meaningful weight-loss results in clinical trials. In the STEP 1 trial, adults taking semaglutide had an average body-weight reduction of 14.9% at 68 weeks. Wegovy also carries FDA approval to reduce the risk of major cardiovascular events in certain adults with obesity or overweight and established cardiovascular disease.
For patients in Muscat, Oman searching for a well-known GLP-1-based option, semaglutide is often the medication people first hear about. Its main strength is that it has a longer clinical track record than the newer agents.
Tirzepatide: the stronger next-generation option
Tirzepatide is the active ingredient in Mounjaro and Zepbound. As with semaglutide, the brand names matter: Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management.
What makes tirzepatide different is that it targets two pathways, GIP and GLP-1, rather than GLP-1 alone. In the SURMOUNT-1 trial, participants on tirzepatide achieved up to 22.5% average weight loss at 72 weeks at the highest dose. In the 2025 head-to-head SURMOUNT-5 trial, tirzepatide also outperformed semaglutide, with 20.2% average weight loss versus 13.7% at 72 weeks. Gastrointestinal side effects were common in both groups and were mostly mild to moderate.
That is why tirzepatide is now widely seen as the stronger currently available option when the goal is greater average weight loss. For many people comparing Mounjaro vs semaglutide in Muscat, Oman, this is the key clinical difference.
Retatrutide: the triple-agonist medication still in trials
Retatrutide is an investigational once-weekly medication developed by Eli Lilly. It activates GIP, GLP-1, and glucagon receptors, making it a triple-agonist treatment rather than a single- or dual-pathway medication. It is not FDA-approved at this time and is still in Phase 3 clinical development.
Earlier clinical data published in the New England Journal of Medicine showed substantial weight-loss results at 48 weeks, and Lilly later announced topline Phase 3 TRIUMPH-4 results showing up to 28.7% average weight loss at 68 weeks in one study population. Even with those results, retatrutide remains investigational and is not yet available for routine public use. Additional Phase 3 readouts are expected in 2026.
So while retatrutide may represent the next wave of medical weight loss, it should still be discussed as a future option rather than a currently accessible treatment.
Quick comparison
Semaglutide
GLP-1 only
Average weight loss around 14.9% at 68 weeks in a major obesity trial
Tirzepatide
GIP + GLP-1
Average weight loss up to 22.5% at 72 weeks in SURMOUNT-1, and 20.2% vs 13.7% against semaglutide in SURMOUNT-5
Retatrutide
GIP + GLP-1 + glucagon
Still investigational, with Phase 2 and early Phase 3 results showing very large weight-loss effects, but not yet FDA-approved
Which option is best for patients in Muscat, Oman?
For people exploring medical weight loss in Muscat, Oman, the most practical comparison today is usually semaglutide vs tirzepatide, because those are the categories of treatment people are most likely to discuss with a qualified medical provider right now. Retatrutide is exciting, but it is still a future-facing option rather than a standard present-day one.
In general, semaglutide remains a strong and established medication, while tirzepatide currently delivers greater average weight-loss results in major studies. The right choice should still depend on your medical history, goals, tolerability, and proper clinical supervision.
Side-by-Side Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Brand Names | Ozempic, Wegovy | Mounjaro, Zepbound | N/A (In Trials) |
| Mechanism | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Average Weight Loss | ~15% (at 68 weeks) | ~21-22% (at 72 weeks) | ~24-28% (at 48-68 weeks) |
| Availability | Prescription | Prescription | Clinical Trials Only |
Final thoughts
The progression from semaglutide to tirzepatide to retatrutide shows how quickly obesity medicine is advancing. Semaglutide helped change the conversation, tirzepatide raised the benchmark for currently available treatment, and retatrutide may push results even further once clinical development is complete.
If you are considering weight loss treatment in Muscat, Oman, the most important step is choosing a clinic that evaluates more than just the medication itself, including your overall health, body composition, progress tracking, and long-term plan.
